enVVeno Medical (NVNO)
(Real Time Quote from BATS)
$5.20 USD
+0.15 (2.97%)
Updated Aug 6, 2024 02:40 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for enVVeno Medical Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 25 | 17 | 9 | 8 |
Income After Depreciation & Amortization | -25 | -25 | -17 | -9 | -8 |
Non-Operating Income | 2 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -24 | -25 | -17 | -9 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -24 | -25 | -17 | -9 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -24 | -25 | -17 | -9 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -24 | -16 | -9 | -7 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -25 | -25 | -17 | -9 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.30 | NA | 8.68 | 1.29 | 0.63 |
Diluted EPS Before Non-Recurring Items | -1.91 | NA | -1.90 | -7.54 | -12.00 |
Diluted Net EPS (GAAP) | -1.91 | -2.20 | -1.90 | -7.54 | -12.00 |
Fiscal Year end for enVVeno Medical Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.46 | 5.50 | 6.28 | 5.35 | 6.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.46 | -5.50 | -6.28 | -5.35 | -6.81 |
Non-Operating Income | 0.50 | 0.51 | 0.63 | 0.35 | 0.34 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.96 | -4.99 | -5.65 | -5.00 | -6.47 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.96 | -4.99 | -5.65 | -5.00 | -6.47 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.96 | -4.99 | -5.65 | -5.00 | -6.47 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 16.07 | 16.06 | 17.65 | 11.23 | 11.23 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.31 | -0.32 | -0.45 | -0.58 |
Diluted Net EPS (GAAP) | -0.31 | -0.31 | -0.31 | -0.45 | -0.58 |